British drugmaker AstraZeneca PLC last week outlined plans to jump-start its widely criticized pipeline by folding in acquired drugs and targeting biologics, in step with an emerging industry-wide trend.
From: www.courierpostonline.com
British drug firm plots strategy to make up for loss of patents
Posted by Ruslan Abuzant at 12:14 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment